Pancreatic ductal adenocarcinoma is among the deadliest cancers we know: nearly 85 percent of people diagnosed die within five years. One reason it is so hard to treat is that a tumor is not one uniform mass of identical cells. A new study shows just how restless those cells are, and why that restlessness matters for treatment.

Looking at cells one by one

Most earlier work analyzed tumor cells in bulk, which is a bit like judging a crowd by its average. Researchers at NYU Langone Health and its Perlmutter Cancer Center took a different route. They measured gene activity in 443,451 single cells from 62 tumors collected from 56 patients. Six of those patients provided samples both before and after chemotherapy.

Grouping cells by their genetic makeup revealed clones, clusters of tumor cells that resemble one another. A typical tumor contained between two and 11 mixes of these clones, drawn from the two broad pancreatic cancer subtypes: classical (less aggressive) and basal (more aggressive).

Clones with different jobs

The clones did not behave alike. Some evolved to resist therapy, while others acquired the ability to spread quickly. According to the team, this ongoing reshaping of the cancer cells’ DNA appears to fuel both treatment resistance and metastasis. It also offers an explanation for something bulk studies could not: how cells move between the classical and basal states. The new results indicate that genetic reconfiguration inside a tumor lets cells make that switch.

MYC and the immune escape routes

One gene stood out. Activity of MYC, a gene long linked to cancer growth, was higher in the aggressive cell populations. When the researchers blocked MYC in basal tumor cells, the cells shifted back toward the less aggressive classical form and became exposed to more immune cells, which could make them more vulnerable to immune attack. This was shown in further experiments on cells, not in patients.

The immune picture is just as interesting. In some clones the TIGIT gene was more active, producing proteins that help cancer cells avoid immune detection. In the same clones, activity of the PD1 gene was suppressed. This may help explain why immunotherapies aimed at PD1 are rarely effective in this disease, although that link is a suggestion from the data rather than a proven mechanism.

What it could mean

Study lead Despoina Kalfakakou described the work as providing “the most granular view to date” of this cancer, and said that targeting the mechanisms behind tumor evolution, MYC included, may help restrain its rapid progression. Co-senior investigator Aristotelis Tsirigos noted that clinical trials of MYC inhibitors and TIGIT inhibitors in pancreatic and other cancers are already underway, and that these findings should encourage larger studies of different cancer cell states and how to treat each one.

The practical takeaway is cautious. This is a descriptive, experimental study of patient tumor samples plus cell experiments. It does not show that any drug works in patients, but it does give researchers a more detailed map of how the disease changes, and a reason to think of a pancreatic tumor as a moving target rather than a fixed one.

Sources